Achilles Therapeutics

About:

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer.

Website: http://achillestx.com/

Twitter/X: achillestx

Top Investors: OrbiMed, RA Capital Management, Invus, Perceptive Advisors, AlbionVC

Description:

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Total Funding Amount:

$213M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2016-05-01

Contact Email:

info(AT)achillestx.com

Founders:

Charles Swanton, Karl Peggs, Mark Lowdell, Sergio Quezada

Number of Employees:

101-250

Last Funding Date:

2022-07-21

IPO Status:

Public

Industries:

© 2025 bioDAO.ai